Cargando…

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations

The majority of invasive mold infections diagnosed in immunocompromised cancer patients include invasive aspergillosis (IA) and mucormycosis. Despite timely and effective therapy, mortality remains considerable. Antifungal agents currently available for the management of these serious infections inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Natesan, Suganthini Krishnan, Chandrasekar, Pranatharthi H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153275/ https://www.ncbi.nlm.nih.gov/pubmed/27994475 http://dx.doi.org/10.2147/IDR.S102207

Ejemplares similares

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

Therapeutic efficacy of isavuconazole in experimental Aspergillus fumigatus endophthalmitis
por: Guest, John, et al.
Publicado: (2017)

Isavuconazole: A Promising Salvage Therapy for Invasive Mucormycosis
por: Shafiq, Muhammad, et al.
Publicado: (2018)

Isavuconazole as salvage therapy for mucormycosis
por: Graves, Bianca, et al.
Publicado: (2016)

Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole
por: Ilharco, Marta, et al.
Publicado: (2019)

Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations
por: Egger, Matthias, et al.
Publicado: (2023)

Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
por: Miceli, Marisa H, et al.
Publicado: (2012)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Breaking the mold: A case of pulmonary mucormycosis treated with isavuconazole
por: Huggins, Jonathan, et al.
Publicado: (2018)

1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
por: Arrieta, Antonio C, et al.
Publicado: (2023)

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

1882. Resistance (R) Trends in Gram-Negative Bacilli (GNB) to Fluoroquinolones (FQ), [Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MOX)], Trimethoprim–Sulfamethoxazole (TMP/SMX) and Nitrofurantoin (NFT) over a 7-Year Period: Pre- and Post-Implementation of FQ Restriction at a Tertiary Care Veterans Affairs Medical Center (VAMC)
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2018)

Gastric Mucormycosis in a Renal Transplant Patient Treated with Isavuconazole Monotherapy
por: Gani, Imran, et al.
Publicado: (2019)

Successful Treatment of Bilateral Renal Mucormycosis With Isavuconazole: A Case Report
por: Najjar, Yaseen, et al.
Publicado: (2023)

Comparison of Clinical Manifestation, Diagnosis, and Outcomes of Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis
por: Lin, Chun-Yu, et al.
Publicado: (2019)

Advances against Aspergillosis and Mucormycosis
por: Stevens, David A.
Publicado: (2020)

824 An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis
por: Marty, Francisco M., et al.
Publicado: (2014)

Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021)

Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole
por: Bassetti, Matteo, et al.
Publicado: (2018)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease
por: Lee, Annie, et al.
Publicado: (2019)

Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support
por: Miller, Michelle, et al.
Publicado: (2022)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature
por: Jacobs, Samantha E., et al.
Publicado: (2017)

Isavuconazole for invasive fungal infections
Publicado: (2020)

836. Significant Elevations in CD4(+) Count, Post-treatment of Chronic Hepatitis C (HCV) with Direct Acting Antivirals (DAAs), in Human Immune Deficiency, HIV/HCV Co-infected Patients with Prolonged CD4+ lymphocytopenia, despite undetectable HIV RNA
por: Kuhn, Ryan, et al.
Publicado: (2021)

Invasive pulmonary mucormycosis and aspergillosis in a patient with decompensated hepatic cirrhosis
por: Persichino, Jon G., et al.
Publicado: (2018)

Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance
por: Ellsworth, Misti, et al.
Publicado: (2020)

1211 A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients
por: Kontoyiannis, Dimitrios, et al.
Publicado: (2014)

360. Breakthrough Invasive Pulmonary Aspergillosis During Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single-Center Experience
por: Fontana, Lauren, et al.
Publicado: (2018)

745. Combination Treatment of Liposomal Amphotericin B and Isavuconazole is Synergistic in Treating Experimental Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

P407 Standardization of PCR for the diagnosis of invasive aspergillosis and invasive mucormycosis from blood samples
por: Rompally, Satwika, et al.
Publicado: (2022)

Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
por: Zuglian, G., et al.
Publicado: (2019)

1172. Mucormycosis Treated with Isavuconazole: A matched-Pair Analysis from the FungiScope(®) Registry
por: Seidel, Danila, et al.
Publicado: (2020)

Oral Mucormycosis and Aspergillosis in the Patient with Acute Leukemia
por: Vučićević Boras, Vanja, et al.
Publicado: (2019)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
por: Banck, Jan Christoph, et al.
Publicado: (2021)

COVID-19 associated with concomitant mucormycosis and aspergillosis
por: Lai, Chih-Cheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m1t6jc5km0j72vou82m60v9vlm